explore -WSS

explore

author：Wikipedia 2025-10-01 15:39:46 - browse：992

Dallas Mavericks owner Mark Cuban reacts during a timeout in the game against the Golden State Warriors at American Airlines Center on March 22, 2023 in Dallas, Texas. – opinion coverage from STAT — Tim Heitman/Getty Images

Mark Cuban, the Dallas Mavericks owner and “Shark Tank” star, has been making headlines recently with his direct-to-consumer venture, Cost Plus Drugs. The company sells generic prescription drugs and boasts more than 2 million members. As a family medicine specialist who has firsthand experience with American households’ dissatisfaction with the state of the nation’s prescription drug marketplace, I believe the enthusiasm for Cost Plus Drugs reveals an appetite for alternatives to the status quo in the pharmaceutical industry.

Cuban claims the reason behind the success of Cost Plus Drugs is the company’s decision to bypass pharmaceutical benefit managers — the negotiating agents insurance companies hire to negotiate big pharma’s prices down. But that might not be the case. Instead, its success appears to lie in its choice to collaborate with affordable generic drug manufacturers rather than the major pharmaceutical companies.

Last year, the Department of Health and Human Services found that between July 2021 and July 2022, major pharma companies raised the list price on more than 1,200 drugs by an average of 31 percent. That’s 23 percent more than the country’s overall inflation rate during the same period. Meanwhile, generic drug companies saved the U.S. roughly $2.6 trillion from 2012 to 2021, according to the Association for Accessible Medicines, a trade group representing generic drug manufacturers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Second House panel advances two

focus

WSS

FDA drug safety: Singulair case shows systemic surveillance flaws

It's time to retire 'poor historian' from clinicians' vocabularies

The real point of Kenneth Smith’s execution by nitrogen gas

Second House panel advances two

Arc Institute generative AI designs new CRISPR systems

With measles on the rise, a personal story of a devastating disease

hotspot

explore

hotspot

Continuity nursing helped my family in our darkest PICU moments

Addiction experts warn against a second 'war on drugs'

How one medical school became remarkably diverse

Readers respond to H5N1 and livestock movements, and more

How one medical school became remarkably diverse

Commercial surrogacy can be ethical, despite pope’s claims

Medical records are filled with copy

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

After affirmative action ruling, medical educators look to 'holistic review'

Venture capitalist Bob Kocher on the state of digital health

hotspot

Helping hospitals and community health centers plan for resilience

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Wearables generate powerful data but its not useful to doctors, yet

ARCH Venture Partners is raising $3 billion for a life sciences fund

Cognito secures funding to test medical device for Alzheimer's

NVIDIA and Google execs on the future of AI and drug discovery

hotspot

knowledge

focus

leisure time